Cardiac Patches Loaded with Stem Cell Factors to Treat Heart Failure
含有干细胞因子的心脏贴片可治疗心力衰竭
基本信息
- 批准号:10229460
- 负责人:
- 金额:$ 75.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-01 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAcute myocardial infarctionAnatomyAnimal ModelAnimalsApplications GrantsBiologicalCardiacCardiac MyocytesCardiomyopathiesCause of DeathCell LineCell TherapyCell TransplantationCellsChronicClinicClinicalClinical ResearchCongestive Heart FailureControl GroupsCuesDegenerative DisorderDevelopmentDisease ProgressionDisease modelEncapsulatedEndothelial CellsEpicardiumExtracellular MatrixFamily suidaeFibroblastsFoundationsFutureHeartHeart DiseasesHeart InjuriesHeart failureHumanImmunologic Deficiency SyndromesIn VitroInfarctionInjectionsIschemiaLigationLogicMembraneModelingMusMyocardialMyocardial InfarctionMyocardiumNatureOperative Surgical ProceduresOrganPatientsProceduresProcessProteinsRattusRegenerative MedicineReperfusion InjuryReperfusion TherapyRiskRodentSafetyStandardizationStem Cell FactorStructureTechnologyTestingTherapeuticTissuesTranslatingTransplantationTumorigenicityWorkadult stem cellbasebiodegradable polymercardiac regenerationcardiac repairclinical translationclinically relevantcytotoxicitydisabilitydonor stem cellextracellular vesiclesheart functionimmunogenicityimplantationimprovedinnovationmouse modelporcine modelpreservationregenerativerelease factorrepair modelrepairedstem cell therapystem cells
项目摘要
PROJECT SUMMARY
Stem cell therapy represents a promising strategy in regenerative medicine. However, live
cells need to be carefully preserved and processed before usage. In addition, cell transplantation
carries certain immunogenicity and/or tumorigenicity risks. The development of cell-free and non-
living therapeutics derived from stem cells has the potential to revolutionize current regenerative
medicine practice. Mounting lines of evidences indicate that stem cells exert their beneficial effects
mainly through the secretion of pro-regenerative factors. Based on this, we fabricated “synthetic
cardiac stem cells (synCSCs)” by encapsulating cardiac stem cell-secreted factors in a biodegradable
polymer block. In a mouse model of myocardial infarction (MI), intramyocardial injection of synCSCs
led to preservation of viable myocardium and augmentation of cardiac functions similar to real CSC
therapy in immunodeficiency mice with myocardial infarction by permanent vessel ligation. Despite
the successful proof of concept, a big challenge is the effective delivery of synthetic cells to the heart.
The present proposal represents a logic progression from our previous work. Here we will be
developing and testing a new entity: an artificial cardiac patch (artCP) formed by embedding
synCSCs into decellularized myocardial extracellular matrix (ECM). Our studies will extend from the
previous rodent acute MI model to a chronic heart failure model in both small/large animals. The
overarching hypothesis is that artCPs can further improve the efficacy of synCSC therapy in rats and
pigs with chronic heart injury. Aim 1 is to fabricate artCPs and determine in vitro potency. Aim 2 is to
demine the safety and efficacy of artCP therapy in a rat model of chronic infarct. Aim 3 is to translate
the findings into a clinically relevant porcine model of advanced cardiomyopathy. Our study will form
the foundation for an innovative and “off the shelf” therapy based on stem cell factors and
myocardium ECM. The cell-free nature of our approach is more readily translatable to the clinic.
Although this particular grant application targets the heart and cardiac stem cells, our approach
represents a platform technology that can be applied to the creation of multiple types of synthetic
stem cell and ECMs for the repair of various other organs.
项目摘要
干细胞治疗是再生医学中一种很有前途的策略。然而,
细胞在使用前需要小心地保存和处理。此外,细胞移植
具有一定的免疫原性和/或致瘤性风险。无细胞和非细胞的发展
来自干细胞的活疗法有可能彻底改变目前的再生
医学实践越来越多的证据表明,干细胞发挥其有益的作用,
主要是通过分泌促再生因子。在此基础上,我们制作了“合成
心脏干细胞(synCSC)”通过将心脏干细胞分泌的因子包封在可生物降解的
聚合物嵌段。在心肌梗死(MI)的小鼠模型中,心肌内注射synCSC
导致存活心肌的保存和心脏功能的增强,类似于真实的CSC
通过永久性血管结扎治疗免疫缺陷小鼠心肌梗死。尽管
成功的概念验证,一个巨大的挑战是有效地将合成细胞输送到心脏。
目前的建议是一个逻辑的进展,从我们以前的工作。我们会在这里
开发和测试一种新实体:通过嵌入形成的人工心脏贴片(artCP)
synCSC转化为脱细胞的心肌细胞外基质(ECM)。我们的研究将从
在小型/大型动物中,将先前的啮齿动物急性MI模型转化为慢性心力衰竭模型。的
总体假设是artCP可以进一步改善synCSC治疗在大鼠中的功效,
慢性心脏损伤的猪目的1制备artCP并测定其体外效价。目标二是
确定artCP治疗慢性梗塞大鼠模型的安全性和有效性。目标3:翻译
将这些发现转化为临床相关的晚期心肌病猪模型。我们的研究将形成
基于干细胞因子的创新和“现成”疗法的基础,
心肌ECM我们的方法的无细胞性质更容易转化为临床。
虽然这个特殊的拨款申请的目标是心脏和心脏干细胞,
代表了一种平台技术,可以应用于创建多种类型的合成
干细胞和ECM用于修复各种其他器官。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ke Cheng其他文献
Ke Cheng的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ke Cheng', 18)}}的其他基金
Drug Delivery and Biomimetic Approaches for Optimal Stem Cell Therapy
最佳干细胞治疗的药物输送和仿生方法
- 批准号:
10370380 - 财政年份:2021
- 资助金额:
$ 75.99万 - 项目类别:
Drug Delivery and Biomimetic Approaches for Optimal Stem Cell Therapy
最佳干细胞治疗的药物输送和仿生方法
- 批准号:
10995606 - 财政年份:2021
- 资助金额:
$ 75.99万 - 项目类别:
Training Grant in Comparative Molecular Medicine
比较分子医学培训补助金
- 批准号:
10202796 - 财政年份:2021
- 资助金额:
$ 75.99万 - 项目类别:
Training Grant in Comparative Molecular Medicine
比较分子医学培训补助金
- 批准号:
10413147 - 财政年份:2021
- 资助金额:
$ 75.99万 - 项目类别:
Surgical Microneedle Patch Delivery of CMMP for Heart Repair
外科微针贴片输送 CMMP 用于心脏修复
- 批准号:
9982489 - 财政年份:2020
- 资助金额:
$ 75.99万 - 项目类别:
Surgical Microneedle Patch Delivery of CMMP for Heart Repair
外科微针贴片输送 CMMP 用于心脏修复
- 批准号:
10586112 - 财政年份:2020
- 资助金额:
$ 75.99万 - 项目类别:
Surgical Microneedle Patch Delivery of CMMP for Heart Repair
外科微针贴片输送 CMMP 用于心脏修复
- 批准号:
10396023 - 财政年份:2020
- 资助金额:
$ 75.99万 - 项目类别:
Modulating Exosome Cargos and Surfaces for Precision Heart Repair
调节外泌体货物和表面以实现精密心脏修复
- 批准号:
10393509 - 财政年份:2019
- 资助金额:
$ 75.99万 - 项目类别:
Harnessing Platelet-Endothelial Interactions for Exosome Delivery
利用血小板-内皮相互作用进行外泌体递送
- 批准号:
10669452 - 财政年份:2019
- 资助金额:
$ 75.99万 - 项目类别:
Cardiac Patches Loaded with Stem Cell Factors to Treat Heart Failure
含有干细胞因子的心脏贴片可治疗心力衰竭
- 批准号:
10005456 - 财政年份:2019
- 资助金额:
$ 75.99万 - 项目类别:
相似海外基金
Non-invasive coronary thrombus imaging to define the cause of acute myocardial infarction
无创冠状动脉血栓显像可明确急性心肌梗塞的病因
- 批准号:
MR/Y009770/1 - 财政年份:2023
- 资助金额:
$ 75.99万 - 项目类别:
Fellowship
Impact of COVID-19 pandemic on pathophysiology of acute myocardial infarction and emergency cardiovascular care system
COVID-19大流行对急性心肌梗死病理生理学和心血管急诊系统的影响
- 批准号:
23K15160 - 财政年份:2023
- 资助金额:
$ 75.99万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Extreme Heat and Acute Myocardial Infarction: Effect Modifications by Sex, Medical History, and Air Pollution
酷热和急性心肌梗塞:性别、病史和空气污染的影响
- 批准号:
10709134 - 财政年份:2023
- 资助金额:
$ 75.99万 - 项目类别:
Development of a multi-RNA signature in blood towards a rapid diagnostic test to robustly distinguish patients with acute myocardial infarction
开发血液中的多 RNA 特征以进行快速诊断测试,以强有力地区分急性心肌梗死患者
- 批准号:
10603548 - 财政年份:2023
- 资助金额:
$ 75.99万 - 项目类别:
Effectiveness of Strategies to Improve Outcomes after Hospitalization for Acute Myocardial Infarction in Older Adults
改善老年人急性心肌梗死住院后预后的策略的有效性
- 批准号:
10576349 - 财政年份:2022
- 资助金额:
$ 75.99万 - 项目类别:
Establishment of the emergency transport decision making program for patients with acute myocardial infarction using artificial intelligence (AI)
利用人工智能(AI)建立急性心肌梗死患者紧急转运决策方案
- 批准号:
22K09185 - 财政年份:2022
- 资助金额:
$ 75.99万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Developing Federated Learning Strategies for Disease Surveillance Using Cross-Jurisdiction Electronic Medical Records without Data Sharing: With Applications to Acute Myocardial Infarction, Hypertension, and Sepsis Detection
使用跨辖区电子病历(无需数据共享)开发疾病监测联合学习策略:在急性心肌梗塞、高血压和脓毒症检测中的应用
- 批准号:
468573 - 财政年份:2022
- 资助金额:
$ 75.99万 - 项目类别:
Operating Grants
Evaluation of effect of intracoronary supersaturated oxygen therapy on inhibition of no reflow phenomenon in acute myocardial infarction
冠状动脉内过饱和氧治疗抑制急性心肌梗死无复流现象的效果评价
- 批准号:
22K08135 - 财政年份:2022
- 资助金额:
$ 75.99万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Effectiveness of Strategies to Improve Outcomes after Hospitalization for Acute Myocardial Infarction in Older Adults
改善老年人急性心肌梗死住院后预后的策略的有效性
- 批准号:
10339915 - 财政年份:2022
- 资助金额:
$ 75.99万 - 项目类别:
The Personalising Acute Myocardial Infarction Care to improve Outcomes (PAMICO Project)
个性化急性心肌梗死护理以改善结果(PAMICO 项目)
- 批准号:
nhmrc : 2005797 - 财政年份:2021
- 资助金额:
$ 75.99万 - 项目类别:
Partnership Projects